Collaborative Practice, a Very High A1c, and an Aunt Without Consent
A Springfield chain pharmacy holds a signed collaborative practice agreement with a local primary care group. It covers adults with type 2 diabetes and authorizes the pharmacist to titrate metformin, basal insulin, and statins, with documentation in the shared record and a quarterly report to the prescriber. A 58-year-old enrollee presents with a fasting log averaging 260 mg/dL, an A1c of 10.9% drawn last week, 3 weeks of polyuria, and 8 lb of unintentional weight loss. She asks the pharmacist to "just start me on something stronger." The same afternoon a 14-year-old arrives with her aunt requesting Tdap and HPV vaccines; the aunt says the mother "is fine with it" but has signed nothing and cannot be reached. A technician has already drawn up the HPV dose.
1. Using only the agreement described, what may the pharmacist do for the diabetes patient right now?
Read the worked answer
The pharmacist may act only inside the four corners of the written agreement, and this presentation exceeds it.
- Within scope: assessing the log, adjusting the basal insulin dose, reinforcing metformin, ordering/interpretation of labs if the agreement allows, documenting, and notifying the prescriber on the agreement's timeline.
- Outside scope: initiating a new drug class (a GLP-1 or SGLT2 inhibitor) is not authorized - "stronger" is not in the agreement. Starting a new agent requires the prescriber.
- Clinical override: polyuria plus 8 lb weight loss plus A1c 10.9% suggests marked insulin deficiency and possible ketosis. That is a red flag for same-day medical evaluation, not a titration visit. The pharmacist should check for nausea, vomiting, abdominal pain, Kussmaul breathing, and check a point-of-care glucose/ketones if available, and refer now - the collaborative agreement does not authorize managing suspected DKA.
- Documentation: record the assessment, the referral, the advice given, and the notification to the PCP. A collaborative agreement expands authority but never converts a pharmacist into an independent prescriber, and the agreement must be in writing, signed, define the drugs and conditions covered, and be available to the Board on request.
2. Can the pharmacist administer the Tdap and HPV vaccines to the 14-year-old?
Read the worked answer
No - not on these facts.
- Massachusetts pharmacists may administer immunizations under a valid protocol or standing order, but for a minor, consent from a parent or legal guardian is required. An aunt is not a consenting authority absent written guardianship or a signed parental consent form. Verbal reassurance that "the mother is fine with it" is not consent.
- The correct sequence is to hold the doses, attempt to reach the parent, and reschedule. Handle it as a paperwork problem, not a refusal - the patient remains eligible.
- When the vaccines are eventually given, the pharmacist must provide the current Vaccine Information Statements, document the vaccine, lot, site, route, dose, date, administering pharmacist, and the consent, and report the administration to the Massachusetts Immunization Information System (MIIS). Only doses actually administered are reported.
- No vaccine may be administered to a minor on a technician's or relative's say-so; the pharmacist is personally accountable for the consent determination.
3. The dose the technician drew up is sitting in the hood. What happens to it, and what governs the technician's role here?
Read the worked answer
The dose cannot be returned to the vial and cannot be administered without consent.
- A drawn-up dose is a prepared product; once it leaves the vial it cannot be re-entered into the multi-dose or single-dose container. If not administered within the manufacturer's/compounding limits and the applicable beyond-use dating, it must be discarded and the waste documented (vaccine, dose, lot, reason, date, initials).
- Technician scope: technicians may perform supporting tasks permitted by the Board and delegated by the pharmacist, but the pharmacist retains responsibility for verifying the right patient, right product, right dose, and right consent before administration. Preparing a dose for an unidentified or unconsented patient is a workflow error the pharmacist must correct, not ratify.
- Preventive fix: verify consent and eligibility before preparation, and keep a written consent form with guardian signature in the profile.